The TVIA Kit(TM) is a revolutionary pharmaceutical product comprised of multiple drug delivery systems to maximize the benefits of CBD
Newport Beach, California–(Newsfile Corp. – May 14, 2019) – Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, today announces the debut of the TVIA Kitâ„˘, a revolutionary medical product containing multiple drug delivery systems for patients who are seeking a non-addictive solution for pain. The three-part system includes only lab-tested, hemp-derived cannabidiol (CBD) products formulated to maximize the benefits of the compound.
A number of statistically significant studies on CBD highlight its anti-inflammatory, antioxidant and neuroprotective properties. The TVIA Kitâ„˘ includes a topical analgesic gel formulated for targeted pain relief and daytime and nighttime dissolvable CBD tablets. The tablets are formulated using Vivera’s license to the internationally patented and U.S. patent-pending TABMELTâ„˘ sublingual drug-delivery system for cannabinoid compounds. The sublingual tablets simply dissolve under the tongue providing the possibility for better absorption when compared to oral delivery by avoidance of the gastrointestinal tract, where stomach acids and liver first-pass metabolism can reduce efficacy.
“The opioid crisis has grown exponentially over the past 20 years and it’s time for a new approach. With the TVIA Kitâ„˘, we are offering patients a product and solution that is much needed,” said Dr. Stephen J. McColgan, Vivera’s Chief Medical Officer. “With multiple non-addictive treatment options including the sublingual CBD tablets and topical analgesic, symptoms can be more easily managed throughout the day and night.”
“Millions of patients are prescribed opioids to help manage pain and the consequences of opioid use can be devastating,” said Olivia Karpinski, Co-Founder and Director of Vivera. “Through Vivera’s ongoing research, if we can help patients manage pain with non-addictive solutions, and even deter them from using opioids in the first place, then we are accomplishing what Vivera has set out to do.”
For more information on the TVIA Kitâ„˘ or Vivera Pharmaceuticals, visit https://viverapharmaceuticals.com.
Figure 1:Â TVIA Kitâ„˘
To view an enhanced version of this graphic, please visit:
About Vivera Pharmaceuticals, Inc.
Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid deterrence and cessation and non-addictive solutions for pain management.
In addition to its pharmaceutical and medical device products, the company has global exclusivity to license the patented and patent-pending TABMELTâ„˘ sublingual drug-delivery system for the pharmaceutical use of cannabinoid compounds.
Vivera Pharmaceuticals is seeking to conduct case studies and clinical trials on CBD in the TABMELTâ„˘ drug delivery format with the goal of gaining FDA approval for its products.
The company is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.
For more information, visit https://viverapharmaceuticals.com.
Investor Relations Inquiries:
Patrick Piette, CFA for Vivera Pharmaceuticals, Inc.
Karin Elz, for Vivera Pharmaceuticals, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/44777